Ethical Concerns about Psilocybin Intellectual Property
- PMID: 33860186
- PMCID: PMC8033603
- DOI: 10.1021/acsptsci.0c00171
Ethical Concerns about Psilocybin Intellectual Property
Abstract
Since a 1957 exposé in Life Magazine, chemical compounds derived from Psilocybe mushrooms have been the focus of dozens of attempted and successful patents, most recently to treat depression. Regrettably, the Mazatec indigenous communities who stewarded these traditional medicines for millenia are not party to any of these patents, despite a number of international treaties asserting indigenous rights to their intangible cultural heritage.
© 2021 American Chemical Society.
Conflict of interest statement
The authors declare no competing financial interest.
Figures

References
-
- Siff S. (2018) R. Gordon Wasson and the Publicity Campaign to Introduce Magic Mushrooms to Mid-Century America. Revue française d’études américaines 156 (3), 91–104. 10.3917/rfea.156.0091. - DOI
-
- Dieter Hagenbach and Lucius Werthmüller (2011). Mystic Chemist: The Life of Albert Hofmann and His Discovery of LSD, Synergetic Press, Santa Fe, NM.
-
- Wooley S. (2020). ‘Magic Mushroom’ Company Goes Mainstream, Jumps 71% Post-IPO. Bloomberg, https://www.bloomberg.com/news/articles/2020-09-18/-magic-mushroom-compa... (accessed 2020-10-14).
-
- James S. L; Abate D.; Abate K. H.; et al. (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study. Lancet 392 (10159), 1789–1858. 10.1016/S0140-6736(18)32279-7. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources